News Releases

Sep 03, 2026

Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

Sep 02, 2026

Climb Bio to Present at Upcoming Investor Conferences

Aug 06, 2026

Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Jun 11, 2026

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Jun 05, 2026

Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development

May 26, 2026

Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026